Drag a card by its title · ⚙ to size, swap or remove

The company

Zymeworks Inc.

ZYME · Nasdaq

Health CareBiotechnologyJust dropped out

ZYME stood above a rising 150-day average in 40 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 1.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Just dropped out
Weeks in an uptrend: out for 1
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $8.4M
Officials’ trades on record: 0
Institutions holding: 197 (-3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 40 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months9

Buyers · sellers0 · 5

Who	Did	Shares	Traded
Adam SchayowitzEVP, Head of R&D	sold	13,832at $25.85	9 Oct 2026filed 9 Oct 2026
Kenneth GalbraithChair & CEO	sold	30,424at $22.67	12 Jan 2026filed 12 Jan 2026
Paul Andrew MooreChief Scientific Officer	sold	9,560at $22.67	12 Jan 2026filed 12 Jan 2026
Jeffrey T. L. SmithEVP & Chief Medical Officer	sold	9,310at $22.67	12 Jan 2026filed 12 Jan 2026
Mark HollywoodEVP & Chief Operating Officer	sold	6,120at $22.67	12 Jan 2026filed 13 Jan 2026
Paul Andrew MooreChief Scientific Officer	sold	9,289at $25.10	5 Jan 2026filed 5 Jan 2026
Paul Andrew MooreChief Scientific Officer	sold	10,821at $25.10	5 Jan 2026filed 5 Jan 2026
Kenneth GalbraithChair & CEO	sold	22,657at $25.10	5 Jan 2026filed 5 Jan 2026
Kenneth GalbraithChair & CEO	sold	31,686at $25.10	5 Jan 2026filed 5 Jan 2026
Jeffrey T. L. SmithEVP & Chief Medical Officer	sold	10,538at $25.10	5 Jan 2026filed 5 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders197-3 on the quarter

New · exited29 · 31

Reported value$1.8B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
EcoR1 Capital, LLCunchanged · filed 14 Aug 2026	22,970,388$600.4M	00.0%
Rubric Capital Management LPunchanged · filed 14 Aug 2026	7,000,000$183.0M	00.0%
BlackRock, Inc.reduced · filed 7 Aug 2026	4,251,030$111.1M	-302,858−6.7%
PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 2026	4,182,953$109.3M	+672,875+19.2%
BVF INCreduced · filed 14 Aug 2026	3,649,142$95.4M	-85,000−2.3%
MORGAN STANLEYreduced · filed 13 Aug 2026	2,231,260$58.3M	-249,308−10.1%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.reduced · filed 13 Aug 2026	1,781,116$46.6M	-126,923−6.7%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026	1,558,998$40.8M	-146,582−8.6%
Assenagon Asset Management S.A.added · filed 8 Jul 2026	1,252,027$32.7M	+524,041+72.0%
Nextech Invest Ltd.unchanged · filed 14 Aug 2026	1,113,946$29.1M	00.0%